Supply Chain

An evaluation by USP indicates bovine heparin is a potential alternative to porcine heparin.

The company has said that all three of its operating sites in China started back up on Feb. 12 and that it is closely monitoring the outbreak.

Researching excipient grades and sources, as well as screening suppliers and materials, form the basis of programs to mitigate risk.

Vein-to-vein programs are focusing on data access and traceability.

GE Healthcare Life Sciences’ new facility for cell and gene processing supplies will be open in 2022.

Aiming to break the bottlenecks that are slowing commercialization of innovative therapies, a new $50-million center in Boston will develop both cell and viral vector products within a single facility.

Applying lessons of raw materials’ characterization and supply-chain control from the semiconductor industry allow more rigorous control of the biopharmaceutical manufacturing process.

Communications and planning are crucial to recovering from supply, operations, and facility disruptions.

The collaboration aims to reduce “vein-to-vein” time for patients and to optimize manufacturing and supply operations.

The partnership combines global CDMO services with a cellular orchestration platform.

Spectrum Laboratory Products received an FDA warning letter after violations were found at its New Brunswick, NJ facility.

The acquisition strengthens BioLife’s position as a supplier of disruptive, enabling solutions used for manufacturing, storage, and distribution of cell and gene therapies.

Machine vision systems have been an integral part of pharma manufacturing and packaging for many years and, with the introduction of stricter safety regulations, are set to become more vital.

As patient-centered therapies and clinical trials become more important, innovation is providing more control and transparency in the way that pharmaceuticals are delivered.

As drug supply chain security is of paramount importance, could radio-frequency identification solutions provide the optimal solution for pharma companies?

With an increased focus on the supply chain security of non-cGMP intermediates, companies need to re-emphasize upstream manufacturing.

Discussing supply chain risk and security as a business led journey, Roddy Martin, chief digital strategist at TraceLink, explains the five stages of its evolution.

Proactive approaches that consider long-term supply chain security compliance are recommended to ensure companies stay on the right track.

Considerations for monitoring impact, vibration, and temperature during package transportation and storage.

TraceLink will participate in the agency’s Pilot Project Program under the Drug Supply Chain Security Act.

A data exchange program between GE Healthcare and Amgen aims to improve biologics manufacturing through analysis of how raw materials affect the process.

Novartis, BMS, and other companies are reducing complexity by thinning out product portfolios. Reducing complexity can reduce waste and improve responsiveness, but it must be done right.

Suppliers address complex supply chains for global biopharmaceutical manufacturing using disposable components.

GS1, a global supply-chain standards organization, launched a new messaging standard in collaboration with GS1 US to help meet the requirements of the US Drug Supply Chain Security Act (DSCSA) for salable returns of serialized prescription drugs.

The strategic partnership is expected to bring a new source of supply to providers, alleviating in particular the two-year shortage of metoprolol injection.

Recent advancements in cold-chain technology offer improved transporting and storing of temperature-sensitive pharmaceutical products.

A new initiative has been launched to help stimulate industry discussion on innovative tech for use across the drug supply chain.

TrakCel and WindMIL Therapeutics have formed a partnership to build a custom-configured cellular supply chain tracking and orchestration platform.

Lonza’s PyroTec PRO system combines robotic liquid-handling technology with an automation software module.

The companies will offer an IT platform that enhances the visibility and performance of the overall personalized medicine treatment process.